UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 25, 2016
ALKERMES PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
Ireland |
|
001-35299 |
|
98-1007018 |
||
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
||
|
of incorporation) |
|
File Number) |
|
Identification No.) |
||
|
|
|
|
||||
|
|
|
|
||||
|
Connaught House, 1 Burlington Road |
|
|
||||
|
Dublin 4, Ireland |
|
|
||||
|
(Address of principal executive offices) |
|
(Zip Code) |
||||
(Registrant's telephone number, including area code): + 353-1-772-8000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Ex-99.1 Press release issued by Alkermes plc dated February 25, 2016 announcing financial results for the year ended December 31, 2015 and financial expectations for the twelve months ending December 31, 2016. |
2
Item 2.02 Results of Operations and Financial Condition
On February 25, 2016, Alkermes plc announced financial results for the year ended December 31, 2015 and financial expectations for the twelve months ending December 31, 2016. A copy of the press release is attached hereto as Exhibit 99.1. This information, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
|
Exhibit |
|
|
|
No. |
|
Description |
|
99.1 |
|
Press release issued by Alkermes plc dated February 25, 2016 announcing financial results for the year ended December 31, 2015 and financial expectations for the twelve months ending December 31, 2016. |
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
ALKERMES PLC
|
|
||
|
Date: February 25, 2016 |
By: |
/s/ James M. Frates |
|
|
|
|
|
James M. Frates |
|
|
|
|
|
Senior Vice President and Chief Financial Officer (Principal Financial Officer) |
|
|
|
|
||||
4
|
|
|
|
|
Exhibit |
|
|
|
No. |
|
Description |
|
99.1 |
|
Press release issued by Alkermes plc dated February 25, 2016 announcing financial results for the year ended December 31, 2015 and financial expectations for the twelve months ending December 31, 2016. |
5
Exhibit 99.1
|
|
Alkermes Contacts: |
|
|
For Investors: Eva Stroynowski, +1 781 609 6823 |
|
|
For Media: Jennifer Snyder, +1 781 609 6166 |
ALKERMES PLC REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED
DEC. 31, 2015 AND PROVIDES FINANCIAL EXPECTATIONS FOR 2016
— Revenues of $628 Million, GAAP Loss Per Share of $1.52 and Non-GAAP Diluted Loss Per Share of $0.36 Reported for Calendar 2015 —
—VIVITROL® Net Sales Grew by 53% Year-Over-Year to $144.4 Million —
— 2016 Revenues Expected to Grow by 15% to 20%, Driven by Continuing Growth of VIVITROL and Launch of ARISTADA® Into Rapidly Growing Long-Acting Antipsychotic Market —
— Pivotal Clinical Programs Underway for Late-Stage CNS Pipeline for Schizophrenia, Multiple Sclerosis and Major Depressive Disorder —
DUBLIN, Ireland, Feb. 25, 2016 — Alkermes plc (NASDAQ: ALKS) today reported financial results for the twelve months ended Dec. 31, 2015 and provided financial expectations for 2016.
“Alkermes has a diversified CNS business poised for significant growth over the coming years. In 2015, we continued to successfully execute on our business plan, highlighted by the robust revenue growth of VIVITROL® and the launch of our novel, long-acting antipsychotic ARISTADA® for the treatment of schizophrenia,” said Richard Pops, Chief Executive Officer of Alkermes. “Looking ahead to 2016, we expect to achieve continued revenue growth and to make significant advances across our pipeline. We will continue to enroll the pivotal clinical studies of ALKS 3831 for schizophrenia and ALKS 8700 for multiple sclerosis; obtain the first clinical data for ALKS 7119, our CNS candidate for Alzheimer’s agitation, and RDB 1450, our immuno-oncology candidate; and report results from the FORWARD-5 efficacy study of ALKS 5461 for major depressive disorder by year-end.”
“Our financial results in 2015 were driven by the strong performance of VIVITROL, the approval and launch of ARISTADA into a rapidly growing long-acting antipsychotic market, and the continued strength of our base business,” commented James Frates, Chief Financial Officer of Alkermes. “In 2016, we expect our business to continue to grow, led by VIVITROL and ARISTADA. Together with our solid royalty and manufacturing base business, these proprietary products are expected to drive revenue growth of 15 to 20 percent.”
Quarter Ended Dec. 31, 2015 Financial Highlights
|
· |
Total revenues for the quarter were $163.1 million. This compared to $175.2 million for the same period in the prior year, or $156.7 million excluding $18.5 million of revenues from the products associated with the Gainesville manufacturing facility that was divested in April 2015 (“the Gainesville Divestiture”). |
|
· |
Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $69.4 million, or a basic and diluted GAAP loss per share of $0.46, for the quarter and reflected increased investment in the company’s advancing late-stage pipeline and commercial infrastructure. This compared to GAAP net income of $30.5 million, or a basic GAAP earnings per share (EPS) of $0.21 and a diluted GAAP EPS of $0.20 for the same period in the prior year, or GAAP net income of $25.2 million, or a basic EPS of $0.17 and a diluted EPS of $0.16, excluding $5.3 million of GAAP net income related to the Gainesville Divestiture. |
|
· |
Non-GAAP net loss was $22.6 million, or a non-GAAP basic and diluted loss per share of $0.15 for the quarter. This compared to non-GAAP net income of $16.8 million, or a non-GAAP basic and diluted EPS of $0.11 for the same period in the prior year, or non-GAAP net income of $9.0 million, or a non-GAAP basic and diluted EPS of $0.06, excluding $7.8 million of non-GAAP net income related to the Gainesville Divestiture. |
Quarter Ended Dec. 31, 2015 Financial Results
Revenues
|
· |
Net sales of VIVITROL were $38.2 million, compared to $29.7 million for the same period in the prior year, representing an increase of 29%. On a unit basis, sales grew 43% compared to the same period in the prior year. Compared to the third quarter of 2015, VIVITROL grew 7% on a unit basis, driven by increased adoption by treatment |
systems, while net sales grew 1% as the company increased accruals for Medicaid rebates to reflect the increasing volume of VIVITROL units covered by Medicaid. |
|
· |
Net sales of ARISTADA were $4.6 million, following its launch in October 2015. |
|
· |
Manufacturing and royalty revenues from RISPERDAL CONSTA®, INVEGA SUSTENNA®/XEPLION® and INVEGA TRINZA® were $75.1 million, compared to $70.3 million for the same period in the prior year. |
|
· |
Manufacturing and royalty revenues from AMPYRA®/FAMPYRA®1 were $19.1 million, compared to $24.3 million for the same period in the prior year, due primarily to the timing of shipments. |
|
· |
Royalty revenue from BYDUREON® was $12.2 million, compared to $9.8 million for the same period in the prior year. |
Costs and Expenses
|
· |
Operating expenses were $230.2 million for the quarter ended Dec. 31, 2015, reflecting increased investment in the company’s development pipeline and the launch of ARISTADA. This compared to $190.8 million for the same period in the prior year, or $177.4 million excluding $13.4 million of operating expenses related to the Gainesville Divestiture. |
Calendar Year 2015 Financial Highlights
|
· |
Total revenues were $628.3 million in calendar 2015, which included VIVITROL net sales of $144.4 million and ARISTADA net sales of $4.6 million. This compared to total revenues of $618.8 million for calendar 2014. Please see the tables at the end of this press release for a detailed breakdown of the revenues from our key commercial products. Excluding the Gainesville Divestiture, 2015 total revenues were $608.6 million in calendar 2015, compared to total revenues of $545.8 million in calendar 2014. |
|
· |
GAAP net loss was $227.2 million, or a basic and diluted GAAP loss per share of $1.52, for calendar 2015 and reflected increased investment in the company’s advancing late-stage pipeline and the launch of ARISTADA in October 2015. This compared to a GAAP net loss of $30.1 million, or a basic and diluted GAAP loss per share of $0.21, for calendar 2014. Excluding the Gainesville Divestiture, GAAP net loss was $231.7 million, or a basic and diluted loss per share of $1.55, in calendar 2015, compared to a GAAP net loss of $53.7 million, or a basic and diluted GAAP loss per share of $0.37, in calendar 2014. |
|
· |
Non-GAAP net loss was $53.2 million, or a non-GAAP basic and diluted loss per share of $0.36, for calendar 2015. This compared to non-GAAP net income of $54.6 million, or a non-GAAP basic EPS of $0.38 and a non-GAAP diluted EPS of $0.35, for calendar 2014. Excluding the Gainesville Divestiture, non-GAAP net loss was $59.5 million, or a non-GAAP basic and diluted loss per share of $0.40, in calendar 2015, compared to a non-GAAP net income of $19.4 million, or a basic and diluted EPS of $0.13, in calendar 2014. |
|
· |
At Dec. 31, 2015, Alkermes recorded cash and total investments of $798.8 million, compared to $801.6 million at Dec. 31, 2014. At Dec. 31, 2015, the company’s total debt outstanding was $349.9 million. |
Financial Expectations for 2016
The following outlines the company’s financial expectations for 2016, which include continued investment in the pipeline and a full year of expenses related to the ARISTADA commercial launch. The following statements are forward-looking, and actual results may differ materially. Please see “Note Regarding Forward-Looking Statements” at the end of this press release for risks that could cause results to differ materially from these forward-looking statements.
|
· |
Revenues: The company expects total revenues to range from $700 million to $750 million, a 15% to 20% increase from 2015 excluding revenues derived from the Gainesville Divestiture, driven by continuing growth of VIVITROL and the ongoing launch of ARISTADA. Included in this total revenue expectation, Alkermes expects VIVITROL net sales to range from $180 million to $200 million. For ARISTADA, the company expects to provide net product revenue guidance during 2016 after gaining additional experience from the launch. |
|
· |
Cost of Goods Manufactured and Sold: The company expects cost of goods manufactured and sold to range from $125 million to $135 million. |
|
· |
Research and Development (R&D) Expenses: The company expects R&D expenses to range from $370 million to $400 million. |
|
· |
Selling, General and Administrative (SG&A) Expenses: The company expects SG&A expenses to range from $360 million to $390 million. |
|
· |
Amortization of Intangible Assets: The company expects amortization of intangibles to be approximately $60 million. |
|
· |
Net Interest Expense: The company expects net interest expense to be approximately $10 million. |
|
· |
Income Tax Expense: The company expects income tax expense of up to $10 million. |
|
· |
GAAP Net Loss: The company expects a GAAP net loss to be in the range of $225 million to $255 million, or a basic and diluted loss per share of $1.48 to $1.68, based on a weighted average basic and diluted share count of approximately 152 million shares outstanding. |
|
· |
Non-GAAP Net Loss: The company expects a non-GAAP net loss to be in the range of $25 million to $55 million, and non-GAAP basic and diluted loss per share to be between $0.16 and $0.36. |
|
· |
Capital Expenditures: The company expects capital expenditures to be approximately $45 million. |
Conference Call
Alkermes will host a conference call at 8:30 a.m. EST (1:30 p.m. GMT) on Thursday, Feb. 25, 2016, to discuss these financial results and provide an update on the company. The conference call may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. In addition, a replay of the conference call will be available from 11:00 a.m. EST (4:00 p.m. GMT) on Thursday, Feb. 25, 2016, through 5:00 p.m. EST (10:00 p.m. GMT) on Thursday, March 3, 2016, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
Non-GAAP net income (loss) adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; non-cash tax expense; deferred revenue; and certain other one-time or non-cash items.
The company’s management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, better indicate underlying trends in ongoing operations and cash flows. However, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: future financial and operating performance, business plans or prospects; the likelihood of continued revenue growth from the company’s commercial products; the therapeutic and commercial value of the company’s products; and expectations concerning the timing and results of clinical development activities. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: clinical development activities may not be completed on time or at all; the results of such clinical development activities may not be positive, or predictive of real-world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company, and its partners, may not be able to continue to successfully commercialize its products; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to governmental payers; the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding the company’s
products; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2015, and in any other subsequent filings made by the company with the Securities and Exchange Commission (“SEC”) and which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release.
VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA® is a registered trademark of Alkermes Pharma Ireland Limited; RISPERDAL CONSTA®, INVEGA SUSTENNA®, XEPLION® and INVEGA TRINZA® are registered trademarks of Johnson & Johnson; AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc.; BYDUREON® is a registered trademark of Amylin Pharmaceuticals, LLC.
1AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is developed and marketed in the U.S. by Acorda Therapeutics, Inc. and outside the U.S. by Biogen Idec, under a licensing agreement with Acorda Therapeutics, as FAMPYRA® (prolonged-release fampridine tablets).
(tables follow)
|
Alkermes plc and Subsidiaries |
||||
|
Selected Financial Information (Unaudited) |
||||
|
|
|
|
|
|
|
|
|
Three Months |
|
Three Months |
|
|
|
Ended |
|
Ended |
|
Condensed Consolidated Statements of Operations - GAAP |
|
December 31, |
|
December 31, |
|
(In thousands, except per share data) |
|
2015 |
|
2014 |
|
Revenues: |
|
|
|
|
|
Manufacturing and royalty revenues |
$ |
119,310 |
$ |
143,202 |
|
Product sales, net |
|
42,816 |
|
29,684 |
|
Research and development revenues |
|
972 |
|
2,275 |
|
Total Revenues |
|
163,098 |
|
175,161 |
|
Expenses: |
|
|
|
|
|
Cost of goods manufactured and sold |
|
34,791 |
|
46,368 |
|
Research and development |
|
93,686 |
|
74,433 |
|
Selling, general and administrative |
|
87,472 |
|
54,804 |
|
Amortization of acquired intangible assets |
|
14,206 |
|
15,244 |
|
Total Expenses |
|
230,155 |
|
190,849 |
|
Operating Loss |
|
(67,057) |
|
(15,688) |
|
Other (Expense) Income, net: |
|
|
|
|
|
Interest income |
|
1,010 |
|
592 |
|
Interest expense |
|
(3,319) |
|
(3,333) |
|
Gain on the Gainesville Transaction |
|
(301) |
|
— |
|
Decrease in the fair value of contingent consideration |
|
(5,000) |
|
— |
|
Gain on sale of property, plant and equipment |
|
2,407 |
|
29,612 |
|
Gain on sale of investment in Civitas Therapeutics, Inc. |
|
— |
|
29,564 |
|
Other (expense) income, net |
|
(533) |
|
33 |
|
Total Other (Expense) Income, net |
|
(5,736) |
|
56,468 |
|
(Loss) Income Before Income Taxes |
|
(72,793) |
|
40,780 |
|
Income Tax (Benefit) Provision |
|
(3,411) |
|
10,266 |
|
Net (Loss) Income — GAAP |
$ |
(69,382) |
$ |
30,514 |
|
|
|
|
|
|
|
(Loss) Earnings Per Share: |
|
|
|
|
|
GAAP (loss) earnings per share — basic |
$ |
(0.46) |
$ |
0.21 |
|
GAAP (loss) earnings per share — diluted |
$ |
(0.46) |
$ |
0.20 |
|
Non-GAAP (loss) earnings per share — basic and diluted |
$ |
(0.15) |
$ |
0.11 |
|
|
|
|
|
|
|
Weighted Average Number of Ordinary Shares Outstanding: |
|
|
|
|
|
Basic — GAAP |
|
150,330 |
|
146,882 |
|
Diluted — GAAP |
|
150,330 |
|
155,527 |
|
Basic — Non-GAAP |
|
150,330 |
|
146,882 |
|
Diluted — Non-GAAP |
|
150,330 |
|
155,527 |
|
|
|
|
|
|
|
An itemized reconciliation between net (loss) income on a GAAP basis and non-GAAP net (loss) income is as follows: |
|
|
|
|
|
Net (Loss) Income — GAAP |
$ |
(69,382) |
$ |
30,514 |
|
Adjustments: |
|
|
|
|
|
Share-based compensation expense |
|
22,869 |
|
13,341 |
|
Amortization expense |
|
14,206 |
|
15,244 |
|
Depreciation expense |
|
7,575 |
|
10,124 |
|
Non-cash taxes |
|
(2,790) |
|
7,324 |
|
Non-cash net interest expense |
|
233 |
|
237 |
|
Deferred revenue |
|
542 |
|
(390) |
|
Decrease in the fair value of contingent consideration |
|
5,000 |
|
— |
|
Decrease in the fair value of common stock warrants |
|
860 |
|
(29,961) |
|
Gain on the Gainesville Transaction |
|
301 |
|
— |
|
Net gain on transactions with equity method investee |
|
(397) |
|
— |
|
Gain on sale of property, plant and equipment |
|
(1,646) |
|
(29,612) |
|
Non-GAAP Net (Loss) Income |
$ |
(22,629) |
$ |
16,821 |
|
Alkermes plc and Subsidiaries |
||||
|
Selected Financial Information (Unaudited) |
||||
|
|
|
|
|
|
|
|
|
Year Ended |
|
Year Ended |
|
Condensed Consolidated Statements of Operations - GAAP |
|
December 31, |
|
December 31, |
|
(In thousands, except per share data) |
|
2015 |
|
2014 |
|
Revenues: |
|
|
|
|
|
Manufacturing and royalty revenues |
$ |
475,288 |
$ |
516,876 |
|
Product sales, net |
|
149,028 |
|
94,160 |
|
Research and development revenues |
|
4,019 |
|
7,753 |
|
Total Revenues |
|
628,335 |
|
618,789 |
|
Expenses: |
|
|
|
|
|
Cost of goods manufactured and sold |
|
138,989 |
|
175,832 |
|
Research and development |
|
344,404 |
|
272,043 |
|
Selling, general and administrative |
|
311,558 |
|
199,905 |
|
Amortization of acquired intangible assets |
|
57,685 |
|
58,153 |
|
Total Expenses |
|
852,636 |
|
705,933 |
|
Operating Loss |
|
(224,301) |
|
(87,144) |
|
Other Income, net: |
|
|
|
|
|
Interest income |
|
3,330 |
|
1,972 |
|
Interest expense |
|
(13,247) |
|
(13,430) |
|
Gain on the Gainesville Transaction |
|
9,636 |
|
— |
|
Decrease in the fair value of contingent consideration |
|
(2,300) |
|
— |
|
Gain on sale of property, plant and equipment |
|
2,862 |
|
41,933 |
|
Gain on sale of investment in Civitas Therapeutics, Inc. |
|
— |
|
29,564 |
|
Gain on sale of investment in Acceleron Pharma Inc. |
|
— |
|
15,296 |
|
Other income (expense), net |
|
15 |
|
(2,220) |
|
Total Other Income, net |
|
296 |
|
73,115 |
|
Loss Before Income Taxes |
|
(224,005) |
|
(14,029) |
|
Income Tax Provision |
|
3,158 |
|
16,032 |
|
Net Loss — GAAP |
$ |
(227,163) |
$ |
(30,061) |
|
|
|
|
|
|
|
(Loss) Earnings Per Share: |
|
|
|
|
|
GAAP loss per share — basic and diluted |
$ |
(1.52) |
$ |
(0.21) |
|
Non-GAAP (loss) earnings per share — basic |
$ |
(0.36) |
$ |
0.38 |
|
Non-GAAP (loss) earnings per share — diluted |
$ |
(0.36) |
$ |
0.35 |
|
|
|
|
|
|
|
Weighted Average Number of Ordinary Shares Outstanding: |
|
|
|
|
|
Basic and diluted — GAAP |
|
149,206 |
|
145,274 |
|
Basic — Non-GAAP |
|
149,206 |
|
145,274 |
|
Diluted — Non-GAAP |
|
149,206 |
|
154,415 |
|
|
|
|
|
|
|
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows: |
|
|
|
|
|
Net Loss — GAAP |
$ |
(227,163) |
$ |
(30,061) |
|
Adjustments: |
|
|
|
|
|
Share-based compensation expense |
|
97,342 |
|
59,579 |
|
Amortization expense |
|
57,685 |
|
58,153 |
|
Depreciation expense |
|
27,911 |
|
39,934 |
|
Non-cash taxes |
|
1,409 |
|
12,379 |
|
Non-cash net interest expense |
|
938 |
|
954 |
|
Deferred revenue |
|
(630) |
|
(997) |
|
Gain on Gainesville Transaction |
|
(9,636) |
|
— |
|
Decrease in the fair value of contingent consideration |
|
2,300 |
|
— |
|
Decrease in the fair value of common stock warrants |
|
302 |
|
— |
|
Net gain on transactions with equity method investee |
|
(1,588) |
|
(28,119) |
|
Gain on sale of property, plant and equipment |
|
(2,101) |
|
(41,933) |
|
Gain on sale of investment in Acceleron Pharma Inc. |
|
— |
|
(15,296) |
|
Non-GAAP Net (Loss) Income |
$ |
(53,231) |
$ |
54,593 |
|
Alkermes plc and Subsidiaries |
|
||||
|
Selected Financial Information (Unaudited) |
|
||||
|
|
|
|
|
|
|
|
Condensed Consolidated Balance Sheets |
|
December 31, |
|
December 31, |
|
|
(In thousands) |
|
2015 |
|
2014 |
|
|
Cash, cash equivalents and total investments |
$ |
798,849 |
$ |
801,646 |
|
|
Receivables |
|
155,487 |
|
151,551 |
|
|
Inventory |
|
38,411 |
|
51,357 |
|
|
Prepaid expenses and other current assets |
|
26,286 |
|
42,719 |
|
|
Property, plant and equipment, net |
|
254,819 |
|
265,740 |
|
|
Intangible assets, net and goodwill |
|
472,059 |
|
573,624 |
|
|
Other assets |
|
109,833 |
|
32,421 |
|
|
Total Assets |
$ |
1,855,744 |
$ |
1,919,058 |
|
|
Long-term debt — current portion |
$ |
65,737 |
$ |
6,750 |
|
|
Other current liabilities |
|
170,470 |
|
123,832 |
|
|
Long-term debt |
|
284,207 |
|
349,006 |
|
|
Deferred revenue — long-term |
|
7,975 |
|
11,801 |
|
|
Other long-term liabilities |
|
13,080 |
|
30,832 |
|
|
Total shareholders' equity |
|
1,314,275 |
|
1,396,837 |
|
|
Total Liabilities and Shareholders' Equity |
$ |
1,855,744 |
$ |
1,919,058 |
|
|
|
|
|
|
|
|
|
Ordinary shares outstanding (in thousands) |
|
150,701 |
|
147,539 |
|
|
|
|
|
|
|
|
|
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Annual Report on Form 10-K for the year ended December 31, 2015, which the company intends to file in February 2016. |
|
||||
|
Alkermes plc and Subsidiaries |
||||||||||
|
Revenues for Calendar Year 2015 and 2014 |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Three Months |
|
Three Months |
|
Three Months |
|
Year |
|
|
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
|
|
March 31, |
|
June 30, |
|
September 30, |
|
December 31, |
|
December 31, |
|
(In thousands) |
|
2015 |
|
2015 |
|
2015 |
|
2015 |
|
2015 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
PARTNERED LONG-ACTING ANTIPSYCHOTICS (1) |
$ |
46,864 |
$ |
60,841 |
$ |
67,606 |
$ |
75,074 |
$ |
250,385 |
|
AMPYRA/FAMPYRA |
|
36,549 |
|
26,939 |
|
22,132 |
|
19,116 |
|
104,736 |
|
BYDUREON |
|
9,800 |
|
11,081 |
|
13,039 |
|
12,195 |
|
46,115 |
|
VIVITROL |
|
31,137 |
|
37,172 |
|
37,903 |
|
38,227 |
|
144,439 |
|
ARISTADA |
|
— |
|
— |
|
— |
|
4,589 |
|
4,589 |
|
Key Commercial Product Revenues |
|
124,350 |
|
136,033 |
|
140,680 |
|
149,201 |
|
550,264 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Legacy Product Revenues (2) |
|
17,314 |
|
13,737 |
|
11,295 |
|
12,925 |
|
55,271 |
|
Gainesville Revenues |
|
19,167 |
|
565 |
|
— |
|
— |
|
19,732 |
|
Research and Development Revenues |
|
383 |
|
1,035 |
|
678 |
|
972 |
|
3,068 |
|
Total Revenues |
$ |
161,214 |
$ |
151,370 |
$ |
152,653 |
$ |
163,098 |
$ |
628,335 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues excluding Gainesville Revenues |
$ |
142,047 |
$ |
150,805 |
$ |
152,653 |
$ |
163,098 |
$ |
608,603 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Three Months |
|
Three Months |
|
Three Months |
|
Year |
|
|
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
|
|
March 31, |
|
June 30, |
|
September 30, |
|
December 31, |
|
December 31, |
|
|
|
2014 |
|
2014 |
|
2014 |
|
2014 |
|
2014 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
PARTNERED LONG-ACTING ANTIPSYCHOTICS (1) |
$ |
49,608 |
$ |
60,001 |
$ |
68,472 |
$ |
70,311 |
$ |
248,392 |
|
AMPYRA/FAMPYRA |
|
20,631 |
|
19,518 |
|
16,503 |
|
24,273 |
|
80,925 |
|
BYDUREON |
|
7,700 |
|
8,784 |
|
10,254 |
|
9,849 |
|
36,587 |
|
VIVITROL |
|
17,079 |
|
21,595 |
|
25,802 |
|
29,684 |
|
94,160 |
|
Key Commercial Product Revenues |
|
95,018 |
|
109,898 |
|
121,031 |
|
134,117 |
|
460,064 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Legacy Product Revenues (2) |
|
16,952 |
|
21,396 |
|
21,203 |
|
21,058 |
|
80,609 |
|
Gainesville Revenues |
|
16,623 |
|
21,067 |
|
16,833 |
|
18,448 |
|
72,971 |
|
Research and Development Revenues |
|
1,619 |
|
1,063 |
|
925 |
|
1,538 |
|
5,145 |
|
Total Revenues |
$ |
130,212 |
$ |
153,424 |
$ |
159,992 |
$ |
175,161 |
$ |
618,789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues excluding Gainesville Revenues |
$ |
113,589 |
$ |
132,357 |
$ |
143,159 |
$ |
156,713 |
$ |
545,818 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) - Includes RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA. |
||||||||||
|
(2) - Includes legacy product revenues excluding product revenues sold as part of the Gainesville Transaction. |
||||||||||
|
Alkermes plc and Subsidiaries |
||||||
|
2016 Guidance — GAAP to Non-GAAP Adjustments |
||||||
|
|
|
|
|
|
|
|
|
An itemized reconciliation between projected loss per share on a GAAP basis and projected loss per share on a non-GAAP basis is as follows: |
||||||
|
|
|
|
|
|
|
|
|
(In millions, except per share data) |
|
Amount |
|
Shares |
|
Loss Per Share |
|
Projected Net Loss — GAAP |
$ |
(240.0) |
|
152 |
$ |
(1.58) |
|
Adjustments: |
|
|
|
|
|
|
|
Non-cash net interest expense |
|
1.0 |
|
|
|
|
|
Non-cash taxes |
|
(5.0) |
|
|
|
|
|
Depreciation expense |
|
32.5 |
|
|
|
|
|
Amortization expense |
|
60.0 |
|
|
|
|
|
Share-based compensation expense |
|
112.5 |
|
|
|
|
|
Deferred revenue |
|
(1.0) |
|
|
|
|
|
Projected Non-GAAP Net Loss |
$ |
(40.0) |
|
152 |
$ |
(0.26) |
|
|
|
|
|
|
|
|
|
Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance. |
||||||